Skip to main content

Table 2 Survival analyses

From: Systemic inflammation and insulin resistance-related indicator predicts poor outcome in patients with cancer cachexia

Variables

OS (model 0) a

OS (model 1) b

OS (model 2) c

OS (model 3) d

Crude HR(95%CI)

Crude P

Adjusted HR(95%CI)

Adjusted P

Adjusted HR(95%CI)

Adjusted P

Adjusted HR(95%CI)

Adjusted P

Total cohort

 As continues (per SD)

1.48 (1.37–1.59)

 < 0.001

1.49 (1.39–1.61)

 < 0.001

1.21 (1.12–1.31)

 < 0.001

1.22 (1.13–1.33)

 < 0.001

By cut-off

 CTI < 4.71

ref

 

ref

 

ref

 

ref

 

 CTI ≥ 4.71

2.12 (1.81–2.47)

 < 0.001

2.12 (1.82–2.48)

 < 0.001

1.44 (1.22–1.70)

 < 0.001

1.45 (1.22–1.71)

 < 0.001

By Interquartile

 Q1

ref

 

ref

 

ref

 

ref

 

 Q2

1.29 (1.01–1.64)

0.041

1.35 (1.06–1.73)

0.015

1.23 (0.96–1.58)

0.101

1.25 (0.97–1.60)

0.081

 Q3

1.99 (1.59–2.50)

 < 0.001

2.02 (1.61–2.54)

 < 0.001

1.48 (1.16–1.87)

0.001

1.48 (1.17–1.88)

0.001

 Q4

2.82 (2.26–3.52)

 < 0.001

2.93 (2.34–3.67)

 < 0.001

1.73 (1.36–2.20)

 < 0.001

1.76 (1.38–2.24)

 < 0.001

 P for trend

 

 < 0.001

 

 < 0.001

 

 < 0.001

 

 < 0.001

By tertiles

 T1

ref

 

ref

 

ref

 

ref

 

 T2

1.56 (1.28–1.91)

 < 0.001

1.60 (1.31–1.96)

 < 0.001

1.41 (1.15–1.74)

0.001

1.40 (1.14–1.73)

0.001

 T3

2.42 (2.00–2.93)

 < 0.001

2.46 (2.02–2.98)

 < 0.001

1.60 (1.30–1.96)

 < 0.001

1.60 (1.30–1.97)

 < 0.001

 P for trend

 

 < 0.001

 

 < 0.001

 

 < 0.001

 

 < 0.001

Internal test cohort

 As continues (per SD)

1.46 (1.25–1.70)

 < 0.001

1.45 (1.24–1.69)

 < 0.001

1.35 (1.12–1.63)

0.002

1.34 (1.11–1.62)

0.002

By cut-off

 CTI < 4.71

ref

 

ref

 

ref

 

ref

 

 CTI ≥ 4.71

1.96 (1.42–2.69)

 < 0.001

1.90 (1.37–2.65)

 < 0.001

1.64 (1.12–2.39)

0.01

1.62 (1.12–2.36)

0.011

By Interquartile

 Q1

ref

 

ref

 

ref

 

ref

 

 Q2

1.62 (0.96–2.76)

0.072

1.36 (0.79–2.36)

0.268

1.22 (0.68–2.17)

0.504

1.22 (0.69–2.18)

0.495

 Q3

2.32 (1.42–3.78)

0.001

2.08 (1.26–3.42)

0.004

1.83 (1.08–3.12)

0.026

1.83 (1.08–3.11)

0.026

 Q4

2.83 (1.77–4.52)

 < 0.001

2.58 (1.60–4.17)

 < 0.001

2.03 (1.17–3.53)

0.012

2.01 (1.16–3.48)

0.013

 P for trend

 

 < 0.001

 

 < 0.001

 

0.005

 

0.006

By tertiles

 T1

ref

 

ref

 

ref

 

ref

 

 T2

1.83 (1.19–2.81)

0.005

1.63 (1.05–2.51)

0.029

1.37 (0.86–2.20)

0.186

1.39 (0.87–2.24)

0.169

 T3

2.61 (1.74–3.91)

 < 0.001

2.43 (1.61–3.69)

 < 0.001

1.97 (1.22–3.16)

0.005

1.93 (1.21–3.10)

0.006

 P for trend

 

 < 0.001

 

 < 0.001

 

0.005

 

0.006

External validation cohort

 As continues (per SD)

1.50 (1.30–1.73)

 < 0.001

1.48 (1.28–1.71)

 < 0.001

1.32 (1.12–1.55)

0.001

1.35 (1.14–1.59)

 < 0.001

By cut-off

 CTI < 4.71

ref

 

ref

 

ref

 

ref

 

 CTI ≥ 4.71

2.17 (1.61–2.92)

 < 0.001

2.12 (1.57–2.87)

 < 0.001

1.59 (1.13–2.24)

0.007

1.61 (1.15–2.26)

0.006

By Interquartile

 Q1

ref

 

ref

 

ref

 

ref

 

 Q2

1.53 (0.94–2.46)

0.084

1.67 (1.03–2.70)

0.039

2.31 (1.37–3.89)

0.002

2.30 (1.36–3.88)

0.002

 Q3

1.97 (1.23–3.16)

0.005

2.00 (1.25–3.22)

0.004

2.15 (1.26–3.66)

0.005

2.16 (1.27–3.70)

0.005

 Q4

3.59 (2.30–5.61)

 < 0.001

3.65 (2.33–5.73)

 < 0.001

3.24 (1.94–5.40)

 < 0.001

3.28 (1.97–5.47)

 < 0.001

 P for trend

 

 < 0.001

 

 < 0.001

 

 < 0.001

 

 < 0.001

By tertiles

 T1

ref

 

ref

 

ref

 

ref

 

 T2

1.46 (0.98–2.18)

0.064

1.50 (1.00–2.24)

0.05

1.72 (1.11–2.68)

0.016

1.71 (1.10–2.67)

0.017

 T3

2.74 (1.89–3.99)

 < 0.001

2.67 (1.83–3.89)

 < 0.001

2.42 (1.56–3.76)

 < 0.001

2.44 (1.57–3.79)

 < 0.001

 P for trend

 

 < 0.001

 

 < 0.001

 

 < 0.001

 

 < 0.001

  1. OS overall survival, HR hazards ratio, CI confidence interval, CTI CRP-TyG index, CRP C-reactive protein, TyG triglyceride-glucose index, BMI body mass index, KPS karnofsky performance status EORTC QLQ-C30 The European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-Core 30 (QLQ-C30), ECOG PS eastern cooperative oncology group performance status, PGSGA Patient Generated Subjective Global Assessment, TSF triceps skinfold thickness
  2. aModel 0: Unadjusted
  3. bModel 1: Adjusted for age, sex, and BMI
  4. cModel 2: Adjusted for age, sex, BMI, tumor stage, tumor types, surgery, chemotherapy, radiotherapy, smoking status, alcohol consumption, KPS, EORTC QLQ-C30, ECOG PS, PGSGA, diabetes, hypertension, and coronary heart disease
  5. dModel 3: Adjusted for age, sex, BMI, tumor stage, tumor types, KPS, surgery, chemotherapy, radiotherapy, smoking status, alcohol consumption, KPS, EORTC QLQ-C30, ECOG PS, PGSGA, diabetes, hypertension, coronary heart disease, and TSF
Back to article page

Cancer & Metabolism

ISSN: 2049-3002